Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Figure 1

PR-104-induced thrombocytopenia followed until death or further treatment. (a) Time-course of thrombocytopenia in each subject at 135 mg/m2 (b) Time-course of thrombocytopenia in each subject at 240 mg/m2 (c) Time-course of thrombocytopenia in each subject at 540 mg/m2 (d) Time-course of thrombocytopenia in each subject at 675 mg/m2 (e) Time-course of thrombocytopenia in each subject at 900 mg/m2 (f) Platelet nadir on first treatment cycle correlated with PR-104 dose-level (Spearman r = -0.79; P < 2 × 10-7).

Back to article page